Early trial tests PRX3-targeting treatment for relapsed mesothelioma
An early-phase trial of RSO-021, a formulation based on the antibiotic thiostrepton, tested whether disabling the antioxidant enzyme PRX3 can make mesothelioma cells vulnerable to oxidative stress. The study reported disease control in 67% of participants; the 15-patient cohort had average progression-free survival of 4.2 months, while researchers described overall-survival findings as encouraging. Phase two has been completed, with results expected at a global oncology meeting this year.